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Proteinuria, a target for renoprotection in patients with type 2
diabetic nephropathy: Lessons from RENAAL.
Background. Proteinuria or albuminuria is an established risk
marker for progressive renal function loss. Albuminuria can be
effectively lowered with antihypertensive drugs that interrupt
the renin-angiotensin system (RAS). We investigated whether
albuminuria could not only serve as a marker of renal disease,
but also function as a monitor of the renoprotective efficacy
of RAS intervention by the angiotensin II (Ang II) antagonist,
losartan, in patients with diabetic nephropathy.
Methods. The data from the RENAAL (Reduction in End
Points in Noninsulin-Dependent Diabetes Mellitus with the An-
giotensin II Antagonist Losartan) study, a double-blind, ran-
domized trial, were used to examine the effects of losartan on
the renal outcome [i.e., the primary composite end point of dou-
bling of serum creatinine, end-stage renal disease (ESRD) or
death] in 1513 type 2 diabetic patients with nephropathy. We
examined the effect of the degree of albuminuria at baseline,
initial antiproteinuric response to therapy, and the degree of
remaining (residual) albuminuria on renal outcome (either the
primary composite end point of RENAAL or ESRD). We also
evaluated the contribution to renal protection of the antipro-
teinuric effect of losartan independently of changes in blood
pressure.
Results. Baseline albuminuria is almost linearly related to
renal outcome, and is the strongest predictor among all mea-
sured well-known baseline risk parameters. After adjusting for
baseline risk markers of age, gender, race, weight, smoking, sit-
ting diastolic blood pressure, sitting systolic blood pressure, to-
tal cholesterol, serum creatinine, albuminuria, hemoglobin, and
hemoglobin A1c (HbA1c) patients with high baseline albumin-
uria (≥3.0 g/g creatinine) showed a 5.2-fold (95% CI 4.3–6.3)
increased risk for reaching a renal end point, and a 8.1-fold
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(95% CI 6.1–10.8) increased risk for progressing to ESRD, com-
pared to the low albuminuria group (<1.5 g/g). The changes in
albuminuria in the first 6 months of therapy are roughly lin-
early related to the degree of long-term renal protection: every
50% reduction in albuminuria in the first 6 months was asso-
ciated with a reduction in risk of 36% for renal end point and
45% for ESRD during later follow-up. Albuminuria at month
6, designated residual albuminuria, showed a linear relation-
ship with renal outcome, almost identical to the relationship
between baseline albuminuria and renal risk. Losartan reduced
albuminuria by 28% (95% CI −25% to −36%), while placebo
increased albuminuria by 4% (95% CI +8% to −1%) in the first
6 months of therapy. The specific (beyond blood pressure lower-
ing) renoprotective effect of the Ang II antagonist, losartan, in
this study is for the major part explained by its antialbuminuric
effect (approximately 100% for the renal end point, and 50%
for ESRD end point).
Conclusion. Albuminuria is the predominant renal risk
marker in patients with type 2 diabetic nephropathy on con-
ventional treatment; the higher the albuminuria, the greater
the renal risk. Reduction in albuminuria is associated with a
proportional effect on renal protection, the greater the reduc-
tion the greater the renal protection. The residual albuminuria
on therapy (month 6) is as strong a marker of renal outcome
as is baseline albuminuria. The antiproteinuric effect of losar-
tan explains a major component of its specific renoprotective
effect. In conclusion, albuminuria should be considered a risk
marker for progressive loss of renal function in type 2 diabetes
with nephropathy, as well as a target for therapy. Reduction of
residual albuminuria to the lowest achievable level should be
viewed as a goal for future renoprotective treatments.
It is estimated that type 2 diabetes affects more than 150
million people worldwide and its prevalence is projected
to double in the next 25 years [1, 2]. Diabetic nephropa-
thy is characterized by hypertension, macroalbuminuria
(proteinuria), progressive loss of renal function, plus a
high incidence of cardiovascular morbidity and mortal-
ity. The four most important risk factors and/or mark-
ers for these outcomes are hyperglycemia, hypertension,
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hyperlipidemia, and proteinuria or albuminuria. Treat-
ment of type 2 diabetes has focused on attenuating hy-
perglycemia, hypertension, and dyslipidemia [3–5].
The predictive power of proteinuria (>500 mg/day)
or albuminuria for progressive renal insufficiency has
been previously demonstrated in patients with diabetic or
nondiabetic renal disease [3, 6, 7]. This risk appears to
be independent of other established risk markers such
as hyperglycemia and hypertension. Several therapeu-
tic options are available to reduce proteinuria. Interrup-
tion of the renin-angiotensin system (RAS) with either
angiotensin-converting enzyme (ACE) inhibitors or an-
giotensin II (Ang II) antagonists is frequently used. These
drugs also lower blood pressure, which has made it dif-
ficult to separate antihypertensive from antiproteinuric
effects as the mediator of renoprotection. To date, no clin-
ical trial has been performed with the primary objective
of studying the effect of suppressing albuminuria with-
out reducing blood pressure on outcomes of renal func-
tion. Data from several clinical trials and a meta-analysis
indicate that blocking the RAS with ACE inhibitors is
more renoprotective than other blood pressure–lowering
strategies; the benefit coincided with a reduction in albu-
minuria in both nondiabetic and type 1 diabetic subjects
[6, 8, 9]. Results from two large clinical trials using Ang
II antagonists to treat type 2 diabetic patients with albu-
minuria, the IDNT Trial [10] and the RENAAL Study
[11], reveal the striking benefits of blocking the RAS
on preserving renal function. We decided to examine if
the renoprotective property of RAS intervention could
be attributed to a reduction in albuminuria, which could
be separated from blood pressure reduction.
Specifically, we examined whether albuminuria is an in-
dependent renal risk marker in type 2 diabetes with kid-
ney disease. Second, we examined whether the degree
of initial reduction in albuminuria would be an indica-
tor of long-term renal protection. Finally, we examined
whether the degree of albuminuria found during contin-
ued therapy (residual albuminuria) was as important risk
factor for kidney damage as was the degree of albumin-
uria at baseline. If these questions are answered posi-
tively, it would suggest that albuminuria is a specific ther-
apeutic target for treating patients with kidney disease in
addition to blood pressure reduction [12].
METHODS
Patients and study design
Results from RENAAL, a multinational, double-blind,
randomized trial comparing losartan versus placebo, each
in addition to conventional antihypertensive therapy, ex-
cluding ACE inhibitors and other Ang II antagonists,
were examined. RENAAL was performed in 28 coun-
tries and in 250 centers and involved 1513 patients. The
study design, inclusion/exclusion criteria, and the treat-
ment protocols have been reported previously [11, 13].
Participants were considered to have type 2 diabetes if
they were older than 30 years at time of diagnosis of di-
abetes, had no history of diabetic ketoacidosis, and did
not require insulin within 6 months of diagnosis. As an
index of nephropathy, urinary albumin:creatinine ratio
>300 mg/g in a first morning void or a 24-hour urine pro-
tein >500 mg was defined as an entry criterion. At the
time of randomization, patients were stratified according
to degree of albuminuria (<2000 mg/g or ≥2000 mg/g).
A serum creatinine >1.5 mg/dL in males (>1.3 mg/dL in
females or males <60 kg) to 3.0 mg/dL, a glycosylated
hemoglobin A1c (HbA1c) <12%, and an age of 31 to
70 years were also part of the inclusion criteria. Patients
with type 1 diabetes or a history of nondiabetic kidney
disease were excluded. Non-ACE inhibitors or Ang II
antagonist antihypertensive therapy (including diuretics,
beta blockers, calcium channel blockers, alpha blockers,
or centrally acting agents) was maintained during the
baseline phase. After the 6-week baseline period, pa-
tients were randomized to treatment with either losartan
or placebo, and were followed for a mean of 3.4 years. All
patients signed informed consent prior to enrollment, and
the study was approved by the local Institutional Review
Board of each participating center.
Prior to randomization and every 3 months post-
randomization, blood samples were obtained to
measure chemistry and hematologic parameters, and a
first-morning urine sample was obtained to measure the
albumin:creatinine ratio (g/g). In a subset of patients
24-hour urine samples also were collected in order to
measure total protein. All blood and urine tests were
performed in a central laboratory. Seated trough blood
pressure was measured three times in a sitting position
after a resting period of at least 5 minutes, and prior
to ingestion of daily antihypertensive medications. The
average of these measurements was recorded. Glomeru-
lar filtration rates (GFR) were not measured in the
study, but estimated for each patient using the modified
Modification of Diet in Renal Disease (MDRD) Study
formula and expressed per 1.73 m2 of body surface area
(BSA) [abstract; Levey AS, et al, J Am Soc Nephrol
11:155A, 2000). The target blood pressure was diastolic
<90 mm Hg and systolic <140 mm Hg.
The primary efficacy parameter was a composite end
point of time to the first event of doubling of serum creati-
nine, end-stage renal disease (ESRD), or death. Doubling
of serum creatinine was defined as the first serum crea-
tinine value that was twice the baseline value, confirmed
with a second serum creatinine value obtained at least
4 weeks after the initial doubling. ESRD was defined
as the need for chronic dialysis or renal transplanta-
tion. Analyses of the components of the primary com-
posite end points also were prespecified. Albuminuria
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(proteinuria) reduction over time between two treatment
groups was one of the secondary end points.
Data analysis
The target of the current analysis focuses on the sec-
ondary end point of albuminuria. Albuminuria was as-
sessed using the ratio of albumin (g/L) to creatinine (g/L)
concentrations from a first-morning urine sample, and
designated “albuminuria” throughout the Results sec-
tion. In a subset of patients actual 24-hour urine was
collected and total protein was measured. For compar-
ison, baseline 24-hour proteinuria data from this subset
are presented as part of the demographic tables. Accord-
ing to the study protocol, albuminuria should have been
collected during the baseline period, and every 3 months
postrandomization for the duration of the study. Base-
line albuminuria was determined by the average of the
last two measurements prior to randomization. Postran-
domization albuminuria at each visit was determined by
a prespecified time window around each scheduled visit.
To analyze therapy-induced changes in albuminuria,
baseline albuminuria was compared with the albumin-
uria at month 6 or the last postrandomization value prior
to the renal event if the event of interest occurred before
month 6. If no postrandomization value was observed
an imputed albuminuria value was used (see Statistical
Analysis section). The 6-month time point for therapy-
induced changes of specified variables was chosen be-
cause this was the earliest time point that most variables
of interest are available, the therapy effect was consid-
ered fully present, and few renal events occurred before
month 6. The albuminuria reduction at month 6 was cal-
culated as 100% × (1 ratio of albuminuria at month 6
over baseline).
In the current analysis, the renal end points are defined
as follows: (1) the primary combined end point of dou-
bling of serum creatinine, ESRD, or death, designated
renal end point; and (2) individual component of ESRD.
For patients who had multiple end points of different
types, only the first occurrence of a renal event was con-
sidered for the renal end point. There were no lost to
follow-up patients; therefore, ESRD or death outcomes
were collected for all randomized patients; collection of
the doubling of serum creatinine component of the renal
end point was considered to be incomplete, due to patient
discontinuation prior to reaching doubling of serum crea-
tinine. Patients who did not have an end point of interest
during the study were considered censored at the study
cutoff date.
Statistical analysis
All 1513 randomized participants in RENAAL were
included in the analysis from randomization through
the study termination date. Patient characteristics, blood
pressure, and laboratory parameters at baseline were
summarized either by treatment group or baseline al-
buminuria categories. Prognostic factors over the study
follow-up were summarized by treatment group. Patients
with a missing value for a given variable at a given
time-point were not included in this summary. Month 6
changes from baseline in prognostic factors were assessed
by month 6 albuminuria categories. For this summary,
missing values for a given variable were imputed (see
below). Mean and standard deviation were provided for
continuous variables, and statistical significance for the
between group comparison was determined based on a
two-sample t test. Number of patients was provided for
categorical variables. Since albuminuria shows a skewed
distribution in this study, averages were expressed as ge-
ometric mean at baseline. Month 6 change from baseline
was expressed as geometric mean ratio (post versus base-
line) by using the natural log (albuminuria) in calculation.
In order to identify risk factors at baseline and therapy-
induced changes in risk factors at month 6 that were in-
dependent predictors of the renal end points, baseline
and baseline and change at month 6 multivariate Cox
models were performed. Baseline risk factors were se-
lected among the following covariates: age, gender, race,
weight, smoking, sitting diastolic blood pressure, sitting
systolic blood pressure, total cholesterol, serum creati-
nine, hemoglobin, HbA1c, and albuminuria. Risk factors
for the therapy induced change analysis were selected
among month 6 changes for weight, sitting diastolic blood
pressure, sitting systolic blood pressure, serum creatinine,
and HbA1c, and albuminuria on the natural log scale. The
change was defined by the difference between month 6
and baseline. The month 6 data were selected in the day
range of 138 to 228 and prior to an end point of interest.
Few patients had events prior to month 6, and the most re-
cent postrandomization value prior to month 6 was used.
For all multivariate analyses, including those described in
the following paragraphs, a backward selection method
was used with the significance level <0.01 for removing
a covariate from the model. The strength of a risk factor
as an independent predictor included in the final analysis
for each endpoint was determined by its magnitude of
significance using chi-squared statistics.
The association between albuminuria and the renal and
ESRD end points were estimated using the Kaplan-Meier
procedure, with baseline albuminuria stratified into three,
post hoc subgroups: <1.5 g/g, ≥1.5<3.0 g/g, and ≥3.0 g/g.
To estimate a risk increase over the subgroup <1.5 g/g, a
multivariate Cox regression model was performed with
indicators of baseline albuminuria subgroups as a factor.
A similar analysis also was done when adjusting for other
baseline covariates described above (with the exception
of albuminuria). To further explore the hazard risk profile
(when adjusting for other baseline covariates), finer cat-
egories (<0.5, ≥0.5<1.5, ≥1.5<3.5, and ≥3.5 g/g) in both
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baseline albuminuria and month 6 residual albuminuria
were used in a similar Cox model with the lowest cate-
gory as a common reference to compute the hazard ratio
and 95% CI for the remainder of the categories. For com-
parison in risk profile (adjusted for other baseline covari-
ates) between two treatment groups, the same categories
(<0.5, ≥0.5<1.5, ≥1.5<3.5, and ≥3.5 g/g) in baseline and
month 6 residual albuminuria were used in the analysis.
The lowest category was used as a common reference for
the placebo treatment group. For the losartan treatment
group, the hazard ratio with 95% CI was referenced by
the corresponding placebo category. Again, the finer cat-
egories were chosen post hoc, with the aim of providing
a smooth risk profile, when adjusting for other baseline
risk factors.
To estimate the effect of albuminuria change on renal
and ESRD end points, analyses similar to baseline al-
buminuria were performed including the Kaplan-Meier
estimates and multivariate Cox regression models when
patients were stratified by three response groups in al-
buminuria reduction at month 6: <0%, ≥0<30%, and
≥30%. In additional to baseline covariates, the previously
described month 6 change variables (with the exception
of log albuminuria) were also included in the adjusted
multivariate analyses. To further explore the hazard risk
profile, finer categories in albuminuria reduction (<−40,
≥−40<−10, ≥−10<10, ≥10<40, ≥40<60, and ≥60%)
were used in a similar Cox model with the lowest cate-
gory as a common reference to compute the hazard ratio
and 95% CI for the remainder of the categories. Again,
these categories were chosen post hoc, with the aim of
providing a smooth risk profile, when adjusting for other
baseline risk factors.
Some patients had missing values for relevant baseline
and month 6 parameters. The number (%) of patients
with missing baseline values are as follows: hemoglobin,
45 (3.0%); HbA1c, 17 (1.1%); total cholesterol, 15 (1.0%);
smoking, 4 (0.3%). It is important to note that no patients
had missing baseline albuminuria or serum creatinine val-
ues. The number (%) of patients with missing month 6 val-
ues (prior to the renal end point) are as follows: HbA1c,
197 (13.0%); albuminuria, 43 (2.8%); serum creatinine,
9 (0.6%); weight, 8 (0.5%); and sitting diastolic blood
pressure or sitting systolic blood pressure, 6 (0.4%). In
order to include all randomized patients into the multi-
variate Cox models (especially to compare the losartan
with placebo groups), missing values either at baseline
or month 6 were populated initially by imputation us-
ing linear regression models. Each dependent variable at
baseline (or month 6) was run in the model with a set
of baseline variables with complete baseline measure-
ments (independent variables), including age, gender,
race, region, blood pressure, weight, prior therapies, and
lab parameters (i.e., serum creatinine, estimated GFR,
albuminuria, blood urea nitrogen (BUN), glucose, serum
potassium, sodium, chloride, and uric acid). A backward
selection method was performed to identify covariates
with a significance level of alpha = 0.05. The indepen-
dent variables in the final model served as the predictors
for patients who had either missing baseline or month 6
values.
The statistical package SAS version 8 was used for this
analysis.
RESULTS
Baseline albuminuria as predictor of renal outcome
Table 1 show the baseline data and risk markers of
the placebo and losartan subgroups, as well as the entire
group of patients. Albuminuria was 1.8 g/g creatinine,
which is equivalent to a proteinuria of 3 g/day with a
range from 0.1 to 15.1 g/day. The degree of proteinuria
was comparable with that measured in the subset of pa-
tients in whom 24-hour urine was collected (3.4 g/day). Of
all the baseline risk markers (age, gender, smoking, eth-
nicity, weight, blood pressure, cholesterol, serum creati-
nine, albuminuria, hemoglobin, and HbA1c) albuminuria
was by far the strongest predictor of both the renal end
point and ESRD (Table 2). Figure 1 shows the Kaplan-
Meier curves for renal end points for three different base-
line albuminuria subgroups. Clearly, the high (≥3.0 g/g)
as well as the intermediate (≥1.5<3.0 g/g) albuminuria
group show significantly more renal events (unadjusted
hazard ratios listed in the figure). Table 3 shows the con-
current baseline values of the other risk parameters in the
three albuminuria groups. Although the baseline values
in the three albuminuria groups were numerically compa-
rable, there were many small statistically significant dif-
ferences observed between the three groups. However,
the effect of these differences on the hazard ratio for al-
buminuria was limited. Adjusted hazard ratios were very
similar for both renal end point and ESRD (Fig. 1). Com-
paring the outcomes of patients in the three groups, and
when adjusting for baseline risk markers, we found that
the renal endpoint was 5.2-fold higher (95% CI 4.3–6.3)
in the high versus the low (<1.5 g/g) albuminuria group.
The high albuminuria group had an 8.1-fold (95% CI 6.1–
10.8) increased risk of progressing to ESRD compared to
the low albuminuria group. To better discern the adjusted
risk associated with different levels of albuminuria, we
analyzed finer categories of albuminuria against the renal
end points. Controlling for other (baseline) risk markers,
we found an almost linear positive relationship between
the degree of baseline albuminuria and the risk for hav-
ing a renal endpoint or for progressing to ESRD (Fig. 2,
left panels).
Reduction in albuminuria as a predictor of renal outcome
Table 4 shows the results of changes in albuminuria,
blood pressure, and other variables from baseline values
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Table 1. Patient demographic and other baseline characteristics in all patients, and stratified for the protocol treatment
Losartan (N = 751) Placebo (N = 762) Total (N = 1513)
Variables Number Mean SD Number Mean SD Number Mean SD
Gender female/male 289/462 268/494 557/956
Race
Asian 117 135 252
African American 125 105 230
Hispanic 140 137 277
Other 11 8 19
White 358 377 735
Smoking yes/no 145/604 128/632 273/1236
Age years 751 60.0 7.4 762 60.3 7.5 1513 60.2 7.4
Weight kg 751 82.6 20.6 762 81.7 20.9 1513 82.2 20.7
Sitting systolic blood pressure mm Hg 751 151.8 18.7 762 153.2 19.9 1513 152.5 19.3
Sitting diastolic blood pressure mm Hg 751 82.4 10.3 762 82.4 10.6 1513 82.4 10.4
Cholesterol mg/dL 743 227.4 55.6 755 228.7 55.4 1498 228.1 55.5
GFR mL/min/1.73 m2 751 39.7 12.0 762 40.0 12.7 1513 39.8 12.3
Hemoglobin A1c% 742 8.5 1.7 754 8.4 1.6 1496 8.5 1.6
Hemoglobin g/dL 732 12.5 1.8 736 12.5 1.8 1468 12.5 1.8
Serum creatinine mg/dL 751 1.9 0.5 762 1.9 0.5 1513 1.9 0.5
Albuminuria mg/g 751 1873 1831 762 1743 1543 1513 1808 1693
(Geometric mean) (1172) . (1148) . (1160) .
Proteinuria mg/daya 350 3478 3487 360 3494 3587 710 3486 3536
(Geometric mean) (2232) . (2216) . (2224) .
GFR is estimated glomerular filtration rate.
Data are given a mean (SD) for continuous variables, and counts for class variables. Smoking status is defined by one year window prior to randomization.
aSubgroup of patients in whom 24-hour urine was collected (see Methods section).
Table 2. Multivariate analysis for the effect of baseline risk markers as well as for the therapy induced change in these risk markers on renal end
point (ordered by statistical significance)
95% CI
End point Multivariate risk markers Hazard ratio Low Up Chi-square P value
At baseline
Renal Albuminuria g/g 1.41 1.36 1.47 <0.0001
Serum creatinine mg/dL 1.91 1.64 2.23 66.9 <0.0001
Hemoglobin g/dL 0.89 0.85 0.93 24.5 <0.0001
Hemoglobin A1c% 1.07 1.02 1.12 8.9 .0028
ESRD Albuminuria g/g 1.45 1.39 1.52 288.7 <.0001
Serum creatinine mg/dL 3.51 2.83 4.36 130.9 <.0001
Hemoglobin g/dL 0.86 0.81 0.92 20.0 <.0001
Age 10 years 0.81 0.70 0.93 9.0 0.0026
At baseline and change at month 6
Renal Serum creatinine change at month 6 mg/dL 4.51 3.84 5.30 332.8 <0.0001
Albuminuria g/g 1.36 1.31 1.42 249.2 <0.0001
Albumin change at month 6 natural log 1.91 1.69 2.16 109.0 <0.0001
Serum creatinine mg/dL 1.45 1.23 1.70 20.0 <0.0001
Hemoglobin g/dL 0.94 0.90 0.98 7.5 0.006
ESRD Serum creatinine change at month 6 mg/dL 3.76 3.13 4.51 201.3 <0.0001
Albuminuria g/g 1.43 1.36 1.51 185.1 <0.0001
Serum creatinine mg/dL 3.43 2.74 4.29 115.2 <0.0001
Albumin change at month 6 on log 2.38 1.99 2.84 91.3 <0.0001
Hemoglobin A1c change at month 6 % 0.86 0.80 0.92 19.0 <0.0001
ESRD is end-stage renal disease.
Top: Baseline risk factors included in the multivariate model are summarized in the Statistical analysis section.
Bottom: Risk factors at baseline and month 6 changes included in the multivariate model are summarized in the Statistical analysis section.
Risk factors are ordered by magnitude of significance as indicated by chi-square statistics.
to those found at 6 months, 1, 2, and 3 years. Results
are available for the total study group as well as for the
subgroups randomized to losartan and placebo treatment
groups. Albuminuria was changed by −14% (95% CI
−11% to −17%) in the first 6 months in the total study
group, by +4% (95% CI +8 to −1%) in the placebo
group, and by −28% (95% CI −25% to −36%) in the
losartan group. The level of albuminuria remained rela-
tively stable during follow-up in the placebo group. The
apparent “fall” observed at 24 and 36 months is likely
linked to “drop out” of patients with high albuminuria in
the placebo group. In the losartan group a slight further
decrease occurred also possibly due to drop out of high al-
buminuria subjects. Additionally, the losartan treatment












































Alb:  ≥1.5<3.0 vs. <1.5 g/g
Alb:  ≥3.0 vs. <1.5 g/g
Alb:  ≥3.0 vs. ≥1.5<3.0 g/g
4.01   <.0001
11.49   <.0001
2.86   <.0001
3.23   <.0001
8.10   <.0001
2.51   <.0001
HR P values HR P values
Adjusted
Alb:  ≥1.5<3.0 vs. <1.5 g/g
Alb:  ≥3.0 vs. <1.5 g/g
Alb:  ≥3.0 vs. ≥1.5<3.0 g/g
2.47   <.0001
6.52   <.0001
2.64   <.0001
2.22   <.0001
5.18   <.0001
2.33   <.0001
HR P values HR P values
Adjusted
Renal end point ESRD
Fig. 1. Event rate of renal end points stratified by baseline albuminuria. The hazard ratio (HR) is shown at the top of each figure. The adjusted
HR is corrected for all measured baseline risk markers summarized in the Statistical analysis section.
Table 3. Patient demographic and other baseline characteristics stratified by baseline albuminuria
Baseline albuminuria
<1.5 (N = 859) ≥1.5<3.0 (N = 365) ≥3.0 (N = 289)
Number Mean SD Number Mean SD Number Mean SD
Gender female/male 270/589 134/231 153/136
Race
Asian 123 73 56
African American 163 45 22
Hispanic 127 70 80
Other 10 2 7
White 436 175 124
Smoking yes/no 150/706 67/297 56/233
Age years 859 61.0 7.2 365 59.7a 7.5 289 58.1a 7.8
Weight kg 859 83.7 19.8 365 81.3 21.1 289 78.5a 22.4
Sitting systolic blood pressure mm Hg 859 149.4 18.6 365 154.5a 19.1 289 159.5a 19.5
Sitting diastolic blood pressure mm Hg 859 82.1 10.7 365 82.2 10.2 289 83.8a 10.0
Cholesterol mg/dL 848 213.2 46.3 364 233.5a 52.3 286 265.3a 64.9
GFR mL/min/1.73 m2 859 42.6 12.2 365 38.0a 11.7 289 33.8a 11.0
Hemoglobin A1c% 849 8.5 1.6 363 8.4 1.5 284 8.6 1.7
Hemoglobin g/dL 832 12.8 1.8 353 12.3a 1.8 283 11.8a 1.7
Serum creatinine mg/dL 859 1.8 0.4 365 1.9a 0.5 289 2.1a 0.5
Albuminuria mg/g 859 695 380 365 2173a 448 289 4652a 1543
(Geometric mean) (571) (2121)a (4449)a
Proteinuria mg/dayb 442 1617 1110 142 4476a 1995 126 8926a 4333
(Geometric mean) (1294) (3865)a (7966)a .
GFR is estimated glomerular filtration rate.
Analysis based on observed data without imputing missing values.
Data are given a mean (SD) for continuous variables, and counts for class variables. Smoking is indicated as the status 1 year prior to randomization.
aThe ≥1.5<3.0 g/g or ≥3.0 g/g groups were compared to the <1.5% g/g group. Statistical significance for these comparisons was based on a two-sample t test, P <
0.05; bSubgroup of patients in whom 24-hour urine was collected (see Methods section).
effect on reduction of albuminuria may have contributed
to the late decline in albuminuria. Systolic blood pres-
sure changed by −3% (95% CI −4% to −2%), +1%
(95% CI −1% to 2%), and −1% (95% CI −2% to 0%)
in the losartan, placebo, and total groups, respectively. Di-
astolic blood pressure changed by −3% (95% CI −4% to
−2%), 0% (95% CI −1% to +1%), and −1% (95% CI
−2% to −1%) in the losartan, placebo, and total groups,
























































<0.5 0.5–1.5 1.5–3.5 ≥3.5







<0.5 0.5–1.5 1.5–3.5 ≥3.5
Albuminuria at month 6, g/g
ESRD
Fig. 2. Hazard ratio for renal events versus
baseline albuminuria (left panels) and ver-
sus albuminuria at month 6 after treatment
start (right panels). The hazard ratio (HR)
with 95% CI is referenced at albuminuria
<0.5 g/g. Relation is corrected for all base-
line risk markers summarized in the Statistical
analysis section.
respectively. Cholesterol and hemoglobin parameters
were not collected at month 6. GFR fell slightly more in
the losartan (10%) group versus placebo (8%, P < 0.09,
NS). Modeling of the initial 6 months change in these dif-
ferent risk parameters for predicting the long-term renal
and cardiovascular risk showed that initial albuminuria
reduction is one of the strongest independent predictors
of both renal outcomes (Table 2).
The change in albuminuria from baseline to 6 months
was highly variable in the total study cohort, and in both
the losartan and placebo-treated groups. When we subdi-
vided the total population into three subgroups accord-
ing to their initial (6 months) antialbuminuric response
(<0%, ≥0<30%, and ≥30% response), renal events oc-
curred more frequently in the groups that had little to no
suppression of albuminuria. In contrast, the groups that
had significant reduction in albuminuria showed fewer
renal events during follow-up (Fig. 3). The changes in
many parameters were significantly greater in the high
(≥30%) albuminuria response group compared to the
low-response (<0%) group (Table 5). However, even af-
ter correcting for these changes in other parameters plus
baseline risk factors, the relative importance of suppress-
ing albuminuria remained strong, since there was little
change in the hazard ratios adjusted for these changes
(see the unadjusted and adjusted hazard Rratios in
Fig. 3). To better discern the adjusted risk associated with
different response levels, we analyzed finer categories of
antialbuminuric response versus the risk for renal out-
come. As shown in Figure 4, for each increase in antial-
buminuric response, there is a decrease in the frequency
of renal events even after correcting for the differences in
other risk factors and baseline risk factors. An increase in
albuminuria in the first 6 months resulted in an increased
renal risk.
Contribution of the antialbuminuric effect
to the renoprotection induced by losartan
Losartan affords renoprotection beyond its blood
pressure–lowering effects [11]. To examine if this
additional renoprotection can be attributed to its
antialbuminuric effect, we followed two strategies. First,
we analyzed the hazard risk for renal events over albu-
minuria at both baseline and after at least up to 6 months
of treatment. In patients starting with the same base-
line albuminuria subsequently randomized to losartan
or placebo, those receiving losartan had a lower risk for
a renal event compared to those treated with placebo,
particularly in those with the high baseline albuminuria
ranges (Fig. 5, left panels, all corrected for other baseline
risk markers). Second, an impact of reduction in albu-
minuria over time on the losartan treatment effect was
investigated. When we adjusted for residual albuminuria
(on the natural logarithm scale), prior to the renal end
point, the treatment effect of losartan on the renal end
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Table 4. Time course of risk markers in all patient and stratified by treatment group
Losartan Placebo TotalTime
Variable Month Number Mean Number Mean Number Mean
Albuminuria mg/g Baseline 751 1172 762 1148 1513 1160
6 679 817 672 1185 1351 983
12 636 714 598 1087 1234 875
24 517 567 500 854 1017 693
36 306 451 269 702 575 555
Sitting systolic blood pressure mm Hg Baseline 751 151.8 762 153.2 1513 152.5
6 714 146.7 706 152.3 1420 149.5
12 674 146.1 657 149.7 1331 147.9
24 562 143.3 534 144.6 1096 143.9
36 334 139.8 288 144.0 622 141.8
Sitting diastolic blood pressure mm Hg Baseline 751 82.4 762 82.4 1513 82.4
6 714 79.7 706 81.6 1420 80.7
12 674 78.3 657 79.9 1331 79.1
24 562 77.0 534 77.4 1096 77.2
36 334 74.7 288 76.2 622 75.4
Cholesterol mg/dL Baseline 743 227.4 755 228.7 1498 228.1
6 35 217.1 41 213.3 76 215.1
12 631 214.3 613 226.4 1244 220.3
24 524 206.9 506 209.9 1030 208.4
36 302 198.1 266 206.4 568 202.0
Serum creatinine mg/dL Baseline 751 1.9 762 1.9 1513 1.9
6 701 2.1 691 2.1 1392 2.1
12 647 2.3 632 2.3 1279 2.3
24 543 2.5 530 2.6 1073 2.5
36 327 2.8 287 2.7 614 2.7
Hemoglobin A1c% Baseline 742 8.53 754 8.43 1496 8.48
6 619 8.59 626 8.56 1245 8.58
12 633 8.55 604 8.51 1237 8.53
24 513 8.58 490 8.51 1003 8.54
36 298 8.38 257 8.41 555 8.39
Hemoglobin mg/dL Baseline 732 12.5 736 12.5 1468 12.5
6 37 11.7 45 12.0 82 11.9
12 625 11.9 598 12.4 1223 12.1
24 516 11.9 489 12.3 1005 12.1
36 298 11.9 258 12.3 556 12.1
Analysis based on observed data without imputing missing values. All laboratory measures occurred prior to end-stage renal disease (ESRD).
Albuminuria is presented as geometric mean.
At each post-randomization time point, a day range was prespecified (for example, days 138 to 228 for month 6 and days 321 to 410 for month 12). If a patient had
more than one measurement in a day range, the measurement in the range which is closest to the center day (day 365 for month 12) was used in the analysis.
point was eliminated: 16.1% (95% CI 2.5% to 27.8%) to
1.7% (95% CI −14.5% to 15.5%). This suggests that the
albuminuria effect is a strong predictor for the renal pro-
tection in this study. A similar analysis was performed for
ESRD alone, demonstrating that when albuminuria was
adjusted over the entire study prior to ESRD, the risk
reduction for ESRD was reduced from 28.6% (95% CI
11.5% to 42.4%) to 14.1% (95% CI −6.6% to 30.8%).
Residual albuminuria
Albuminuria at 6 months is designated as residual al-
buminuria, reflecting the albuminuria that remains de-
spite “maximal” treatment per protocol. Interestingly,
the residual albuminuria also demonstrated a relation-
ship with long-term renal outcome. Specifically, the more
albumin that is excreted in the urine, the more risk for
a subsequent renal event (Fig. 2, right panels). In fact,
when comparing the relationship between baseline al-
buminuria and renal risk with the 6 months residual
albuminuria and renal risk, these curves show complete
overlap. The importance of residual albuminuria even
during therapy is further shown by the finding that the
residual albuminuria level after reduction with losartan
confers the same renal risk as such a (unchanged) albu-
minuria level in a placebo patient (Fig. 5, right panels).
DISCUSSION
Results from the current study show that albuminuria
is the most powerful marker for subsequent renal events
in type 2 diabetic subjects with nephropathy. Reduction
of albuminuria during the first 6 months of treatment was
clearly evident in patients treated with the Ang II antag-
onist, losartan. The antiproteinuric effect of losartan ap-
pears to explain most of the renoprotection conferred by
this agent, and is beyond that which could be attributed to
the effect of this agent on blood pressure. Suppression of
albuminuria was an independent predictor of long-term
protection from renal events. Interestingly, the degree of









































∆ Alb:  ≥0<30 vs. <0%
∆ Alb:  ≥30 vs. <0%
∆ Alb:  ≥30 vs. ≥0<30%
0.88   0.1570
0.60   <.0001
0.68   0.0003
0.76   0.0028
0.46   <.0001
0.61   <.0001
HR P values HR P values
AdjustedUnadjusted
∆ Alb:  ≥0<30 vs. <0%
∆ Alb:  ≥30 vs. <0%
∆ Alb:  ≥30 vs. ≥0<30%
0.82    0.1242
0.51    <.0001
0.62    0.0019
0.62   <.0003
0.37   <.0001
0.60   0.0010
HR P values HR P values
AdjustedUnadjusted
Renal end point ESRD
Fig. 3. Event rate of renal end points stratified by albuminuria change from baseline to 6 months. The hazard ratio (HR) is shown at the top of each
figure. The adjusted HR is corrected for all measured baseline risk markers, and month-6 changes summarized in the Statistical analysis section.
Table 5. Response of different risk markers to antihypertensive treatment in the first 6 months stratified according to albuminuria reduction at
month 6
Albuminuria reduction at month 6
<0% (N = 631) ≥0<30% (N = 393) ≥30% (N = 489)Variable for change from
baseline at month 6 Mean change SD Mean change SD Mean change SD
Weight kg 0.7 2.8 0.3a 2.9 0.4 3.3
Sitting systolic blood pressure mm Hg 1.0 16.7 −3.9a 16.2 −6.6a 16.5
Sitting diastolic blood pressure mm Hg −0.0 8.9 −2.2a 8.0 −3.8a 7.9
Hemoglobin A1c % 0.1 1.4 0.1 1.4 0.1 1.5
GFR mL/min −2.6 6.4 −3.6a 5.7 −3.8a 5.8
Serum creatinine mg/dL 0.3 0.5 0.3 0.5 0.3 0.4
Albuminuria mg/g 634 775 −339a 399 −884a 905
Albuminuria reduction % +50 −20a −60a
GFR is estimated glomeruclar filtration rate. The analysis was based on all randomized patients whose missing data at baseline and month 6 were imputed, see details
in Statistical analysis section. Only the observed data prior to end-stage renal disease (ESRD) was included in the analysis.
Albuminuria reduction was geometric mean ratio at month 6 over baseline, expressed as % change from baseline.
aThe ≥0<30% or ≥30 % reduction groups were compared to the <0% group. Statistical significance for these comparisons was based on a two-sample t test, P <
0.05.
residual albuminuria remains proportionally associated
with renal risk, and its relationship is similar as that ob-
served with albuminuria before start of treatment. Thus,
suppressing albuminuria is associated with a reduction in
risk and it is predicted that additional suppression of al-
buminuria would be associated with additional end-organ
protection. Specifically, we demonstrated that the greater
the reduction in albuminuria over the initial 6 months,
and the lower the albuminuria after 6 months of treat-
ment, the less likely the patient would experience a renal
outcome. Therefore, albuminuria should be further ex-
plored as a prime target in type 2 diabetic patients with
nephropathy, potentially, and should be a key considera-
tion in determining drug choice as well as the drug dose,
irrespective of the blood pressure.
Albuminuria has long been known to be a marker of
the severity of kidney disease [14]. The prevailing opinion
was that albuminuria was primarily a marker of renal in-
jury and that the more the kidney was damaged, the more
it would leak plasma proteins. Remuzzi and Bertani [15]
challenged this idea and hypothesized that albuminuria
itself could damage the kidney cell. Although a cause-
effect relationship for albuminuria and progressive kid-
ney damage is hard to identify clinically, albuminuria is a
strong risk marker in diabetes [16–18] as well as in non-
diabetic renal disease [19]. The results from the present
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Fig. 4. Change in albuminuria (baseline compared to month 6) versus the hazard ratio of renal end point. The hazard ratio (HR) is adjusted for
all baseline risk markers as well as the initial 6-month changes summarized in the Statistical analysis section. The HR with 95% CI is calculated
relative to 0% change in albuminuria.
study obtained in this large, prospective clinical trial show
that this phenomenon also applies to the clinical context
of the patient with type 2 diabetes.
Since the discovery that blood pressure and choles-
terol are independent risk markers for renal events, ther-
apeutic strategies have been designed and tested to lower
the blood pressure and serum cholesterol. These studies
determined that lowering blood pressure and/or serum
cholesterol appeared to be associated with reduced kid-
ney risks [20, 21]. There are therapeutic strategies that can
reduce the degree of albuminuria, including low protein
diet [22], indomethacin [23], the antihypertensive agents
such as ACE inhibitors [24, 25], or Ang II antagonists
[26, 27]. In particular, the latter two drug classes are well
known for their antiproteinuric effect in a variety of re-
nal diseases. Large clinical trials such as the collaborative
trial [9] in type 1 diabetes, and the AIPRI study [28] in
nondiabetic renal disease have shown that the renal pro-
tection of RAS intervention is associated with a lower
level of albuminuria. Unfortunately in those studies, the
RAS intervention led to lower blood pressure levels than
observed with the control therapies. Thus, it remained
speculative whether the changes in albuminuria per se
affected the renal endpoints independently of blood pres-
sure. However, the REIN study in nondiabetic renal dis-
ease clearly showed that lowering of albuminuria in the
ACE inhibitor arm is associated with renal protection be-
yond blood pressure effects [29].
The current study has clearly demonstrated that al-
buminuria reduction in type 2 diabetic nephropathy is
associated with renal protection. One of the arguments
in favor of albuminuria itself being detrimental to the
kidney has been the fact that the degree of reduction
of albuminuria predicts the renal outcome. This has been
demonstrated in relatively small studies in type 1 diabetes
[30] and in nondiabetic renal disease [31]. Confirmed by
retrospective analysis in large trials in type 1 diabetes [17],
and in nondiabetic patients in the MDRD [19], these re-
sults positioned albuminuria next to high blood pressure
as a potential independent target for therapy. The cur-
rent study for the first time shows on a large scale, in a
prospective manner that the degree of albuminuria re-
duction is related in a linearly manner to the subsequent
renal protection in type 2 diabetes. A particularly impor-
tant finding of the present study was the fact that the
relationship between albuminuria and renal risk remains
present both before and after albuminuria lowering ther-
apy. For example, 2 g albuminuria in a patient not tak-
ing losartan carries the same risk as 2 g albuminuria in
a patient receiving losartan. This would imply that albu-
minuria is a damaging marker irrespective of the absence
or presence of Ang II inhibition/antagonism. This would
suggest that further lowering of the residual albuminuria
by additional approaches should still be considered.
Blood pressure control was an important part of the
treatment of all patients participating in this trial. The
use of other antihypertensive drugs was well balanced be-
tween the different albuminuria subgroups and the albu-
minuria response groups, even though patients were not
randomized into albuminuria subgroups. These groups
did have small differences in responses of other risk
markers such as blood pressure and cholesterol but the
impact of these changes did not explain the observed
“antialbuminuric effect.” Regardless, we recognize there
could have been other characteristics coinciding with the
presence or the change in albuminuria that we did not
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Fig. 5. Hazard ratio for renal events versus albuminuria stratified for study drug. The left panel is the relation of the renal end point and end-
stage renal disease (ESRD) against baseline albuminuria, The right panel is the relation between the renal end point and ESRD against month 6
albuminuria. Relation is corrected for baseline risk markers, as summarized in the Statistical analysis section. The <0.5 g/g category in the placebo
group was used as a common reference for the losartan and placebo groups.
measure, and that such changes may have influenced the
outcome. However, the current results indicate the need
to design future studies by assigning special attention to
changes in albuminuria as an index of the risk of renal
outcomes, especially when other clinical outcome studies
confirm the finding from the RENAAL Study.
The findings of the RENAAL Study extend the concept
that suppressing albuminuria should be further explored
as a goal of therapy to achieve optimal renal protection
in the individual patient with type 2 diabetes. The drug
of choice would very likely be an ACE inhibitor or an
Ang II antagonist. One could argue that titration of drug
dosage based on changes in blood pressure would be suf-
ficient to ensure an optimal antiproteinuric effect, but
from other studies in type 1 diabetes and nondiabetic re-
nal disease, the dose-response curve for blood pressure
and albuminuria appear to be different [32–34]. These
data emphasize the need for new studies where the pri-
mary target is reduction of albuminuria. It is our advice
that guidelines on individual therapies in type 2 diabetes
should not only mention albuminuria as an important
risk factor/marker, but should also define albuminuria as
a target for therapy choice as well as dose of treatment,
independent of blood pressure. As with blood pressure,
therapy strategies should be guided with the sole aim to
reduce albuminuria to the lowest achievable level.
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